MTOR and cancer: Since it is increasingly recognized that the mTOR pathway has manifold functions as a central regulator of cell metabolism [6, 40], the mTOR inhibitors including rapamycin are in clinical use as an immunosuppressive treatment to prevent organ transplant rejection [41–43] and stent restenosis [44, 45] or as an anti-cancer therapy [46, 47].